Baker & McKenzie LLP
09/23/2025 | Press release | Distributed by Public on 09/23/2025 07:53
Baker McKenzie Advises Asabys in an Oversubscribed Series C Funding Round for SafeHeal Totaling EUR 10 million
Baker McKenzie advised the investment fund Asabys in an oversubscribed Series C funding round for SafeHeal, totaling EUR 10 million. This fundraising will enable SafeHeal to accelerate the commercialization of Colovac®, an innovative medical device for patients with colorectal cancer.
The extension round was led by Asabys Partners through its Sabadell Asabys II fund, joining a world-leading syndicate that includes Sofinnova Partners, Solar Eclipse, Gideon Strategic Partners, Polis and M&L Healthcare.
The Baker McKenzie team was composed of the following:
• Corporate: Antoine Caillard (Senior Counsel, Paris); David Courchia (Senior Associate, Paris); Carlos Martin (Partner, Madrid); Emily Nash (Associate, Chicago)
• Employment Law: Jérémie Paubel (Partner, Paris); Roland Sèbe (Associate, Paris)
The extension round was led by Asabys Partners through its Sabadell Asabys II fund, joining a world-leading syndicate that includes Sofinnova Partners, Solar Eclipse, Gideon Strategic Partners, Polis and M&L Healthcare.
The Baker McKenzie team was composed of the following:
• Corporate: Antoine Caillard (Senior Counsel, Paris); David Courchia (Senior Associate, Paris); Carlos Martin (Partner, Madrid); Emily Nash (Associate, Chicago)
• Employment Law: Jérémie Paubel (Partner, Paris); Roland Sèbe (Associate, Paris)
Baker & McKenzie LLP published this content on September 23, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on September 23, 2025 at 13:53 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]